Examining a stock’s 52-week price history, encompassing its low and high prices, can reveal much about its existing condition and potential future trajectory. Moderna Inc’s current trading price is -69.86% away from its 52-week high, while its distance from the 52-week low is 19.78%. The stock’s price range over this period has fluctuated between $23.15 and $91.99. The company, operating within the financial sector, had a trading volume of approximately 3.2 million for the day, which was noticeably lower than the average daily share volume of 10.91 million over the last 3 months.
Moderna Inc (MRNA) stock is currently valued at $27.73. During the last session, the stock experienced a remarkable rise, reaching $198.0 after opening at $27.64. The stock briefly dropped to $20.0 before ultimately closing at $27.6.
In terms of market performance, Moderna Inc had a fairly uneven. The highest value for the stock in the past year was $91.99 on 08/19/24, and the lowest value was recorded at $23.15 on 04/07/25.
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
Moderna Inc (MRNA) has experienced a quarterly rise of 0.43% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 10.72B and boasts a workforce of 5800 employees.
Moderna Inc: What Analysts Are Saying
As of right now, 4 analysts are rating Moderna Inc as a BUY, 1 of the polled analysts branded the stock as an OVERWEIGHT, 16 analysts are recommending to HOLD this stock, 3 of them gave the stock UNDERWEIGHT rating, and 1 analyst is rating the stock as SELL.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 28.57, with a change in price of -6.12. Similarly, Moderna Inc recorded 10,093,257 in trading volume during the last 100 days, posting a change of -18.12%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for MRNA stands at 0.08. Similarly, the long-term debt-to-equity ratio is also 0.07.
MRNA Stock Stochastic Average
Today, Moderna Inc’s raw stochastic average for the past 50 days stands at 24.51%, indicating a rise from the raw stochastic average of the last 20 days, which was 11.92%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 9.14% and 23.87% respectively.
MRNA Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. Until today this year the stock’s price performance recorded a decrease of -76.74%. However, over the last six months, the performance has been stronger by -29.66%. The price of MRNA decreased -9.06% over the last 30 days. And in the last five days, it has fallen by -18.23%.
